Related references
Note: Only part of the references are listed.Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination
Robert A. Eisenberg et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2013)
Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant
Diego Villa et al.
LEUKEMIA & LYMPHOMA (2013)
A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia
Donald M. Arnold et al.
BLOOD (2012)
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia
Vivek L. Patel et al.
BLOOD (2012)
Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia
Nichola Cooper et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Risk of Invasive Haemophilus influenzae Type b (Hib) Disease in Adults with Secondary Immunodeficiency in the Post-Hib Vaccine Era
Eli B. Nix et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
A Prospective Study of the Factors Shaping Antibody Responses to the AS03-Adjuvanted Influenza A/H1N1 Vaccine in Cancer Outpatients
Andreas F. Hottinger et al.
ONCOLOGIST (2012)
Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma
Chun-Hung Cho et al.
ANNALS OF HEMATOLOGY (2011)
Impact of Synthetic and Biologic Disease-Modifying Antirheumatic Drugs on Antibody Responses to the AS03-Adjuvanted Pandemic Influenza Vaccine A Prospective, Open-Label, Parallel-Cohort, Single-Center Study
Cem Gabay et al.
ARTHRITIS AND RHEUMATISM (2011)
Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases
S. van Assen et al.
AUTOIMMUNITY REVIEWS (2011)
Seroprotective Titers against 2009 H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Recipients
Nicolas C. Issa et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment
Olav Erich Yri et al.
BLOOD (2011)
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
Cindy Neunert et al.
BLOOD (2011)
Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: Prepared on behalf of the British Committee for Standards in Haematology by a Working Party of the Haemato-Oncology Task Force
John M. Davies et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host
Hugues de Lavallade et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Effect of rituximab on human in vivo antibody immune responses
Mark D. Pescovitz et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment
Helen J. Mackay et al.
JOURNAL OF CLINICAL VIROLOGY (2011)
The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab
U. Arad et al.
VACCINE (2011)
The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases
Nichola Cooper et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
American Society of Clinical Oncology Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection Screening in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases
Andrew S. Artz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Hepatitis B Virus Reactivation After 23 Months of Rituximab-based Chemotherapy in an HBsAg-negative, Anti-HBs-positive Patient With Follicular Lymphoma
I-Cheng Lee et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2010)
Stimulation of anti-polio and anti-HSV IgA pre-plasma cell response in blood following parenteral immunization with tetanus-diphtheria vaccine
Jason R. Fernandes et al.
VACCINE (2010)
Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment
Maria Rehnberg et al.
ARTHRITIS RESEARCH & THERAPY (2010)
The Long-term Impact of Rituximab for Childhood Immune Thrombocytopenia
Nichola Cooper et al.
Current Rheumatology Reports (2010)
Risk for Hospital Contact With Infection in Patients With Splenectomy A Population-Based Cohort Study
Reimar W. Thomsen et al.
ANNALS OF INTERNAL MEDICINE (2009)
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Kenneth R. Carson et al.
BLOOD (2009)
Requirement of B Cells for Generating CD4+ T Cell Memory
Jason K. Whitmire et al.
JOURNAL OF IMMUNOLOGY (2009)
Monoclonal anti body-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project
Kenneth R. Carson et al.
LANCET ONCOLOGY (2009)
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab
Roberto Stasi et al.
BLOOD (2008)
Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy
Clara Targhetta et al.
HAEMATOLOGICA (2008)
Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response
S. Oren et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Assessment and clinical interpretation of polysaccharide antibody responses
Kenneth Paris et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2007)
Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura
Roberto Stasi et al.
BLOOD (2007)
Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura
Donald M. Arnold et al.
ANNALS OF INTERNAL MEDICINE (2007)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Immunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in southwestern Alaska
Henry C. Baggett et al.
CLINICAL AND VACCINE IMMUNOLOGY (2006)
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
SM Horwitz et al.
BLOOD (2004)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications
K Kojouri et al.
BLOOD (2004)
Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP)
J Schwartz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2003)
Maintenance of serological memory by polyclonal activation of human memory B cells
NL Bernasconi et al.
SCIENCE (2002)
Risk of infection and death among post-splenectomy patients
N Bisharat et al.
JOURNAL OF INFECTION (2001)
Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management
XR Luo et al.
REVIEWS IN MEDICAL VIROLOGY (2001)
Morbidity and mortality in adults with idiopathic thrombocytopenic purpura
JEA Portielje et al.
BLOOD (2001)
Share Paper
